Corporate Investor

Updated:

Vivozon

Vivozon was established in 2008 by Doo-Lee Lee in Yongin-si, South Korea. The company functions as both a drug developer and corporate investor, concentrating...

Vivozon logo

Vivozon

Vivozon was established in 2008 by Doo-Lee Lee in Yongin-si, South Korea. The company functions as both a drug developer and corporate investor, concentrating resources on pharmaceutical raw materials and finished products. Its investment approach spans seed, start-up, and late-stage venture commitments. Capital supports internal programs and external opportunities in pain medicine and central nervous system therapies. Geographic reach includes South Korea headquarters and plant operations plus a New Jersey office. Confirmed partners include Telcon RF Pharmaceutical through prior strategic arrangements. The firm employs an estimated 66 million dollars in assets. It maintains two South Korean sites and one U.S. location. Vivozon lists donations to the Community Chest of Korea and the International Vaccine Institute. Ownership remains tied to founder Lee Doohyun with no disclosed external governance vehicles or succession structures beyond direct corporate control.

General information

Firm type

Corporate Investor

Year founded

2008

AUM

Undisclosed

Location

Region

Asia

Country

South Korea

City

Yongin-si

Corporate office

Yongin-si, Gyeonggi-do, South Korea

Additional offices

Hwaseong, Gyeonggi-do, South Korea · West Windsor, NJ, United States

Principals

Doo-Lee Lee

Founder, Chairman, and CEO

Sector focus

Healthcare Services

Frequently asked questions

Who runs investment decisions at Vivozon?

Doo-Lee Lee serves as Founder, Chairman, and CEO and directs investment activity.

What asset classes does Vivozon deploy into?

Vivozon commits to early-stage seed, start-up, and expansion venture opportunities in pharmaceuticals.

Does Vivozon maintain facilities outside South Korea?

Yes. It operates a West Windsor, New Jersey office in addition to its Yongin-si headquarters and Hwaseong plant.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Yongin-si Corporate Investor profiles